# **Azithromycin Eye Drops**

Azithromycin Eye Drops are a sterile solution of Azithromycin in a suitable oily vehicle.

Azithromycin Eye Drops contain not less than 90.0 per cent and not more than 105.0 per cent of the stated amount of azithromycin,  $C_{38}H_{72}N_2$   $O_{12}$ .

Usual strength. 1.0 per cent w/v.

#### **Identification**

A. Add 10 ml of *ethanol* to a quantity of the eye drops containing 100 mg of azithromycin and mix. Allow to stand, retain the upper ethanolic layer and evaporate it to dryness under a stream of nitrogen. Wash the residue with 10 ml of *hexane* followed by a further 50 ml of *hexane* and allow to dry in air, the residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with azithromycin RS treated in the same manner or with the reference spectrum of azithromycin:

B. In the test for Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the principal peak in the chromatogram obtained with the reference solution (a).

#### **Tests**

**Related substances**. Determine by liquid chromatography (2.4.14).

*NOTE* — *Prepare the solutions immediately before use.* 

Solvent mixture. 20 volumes of dichloromethane and 80 volumes of methanol.

Test solution. Dilute a volume of the eye drops containing 8 mg of Azithromycin to 100.0 ml with the solvent mixture.

Reference solution (a). Dilute 1 ml of the test solution to 100 ml with the solvent mixture.

Reference solution (b). A solution containing 0.01 per cent w/v of azithromycin RS and 6-demethyl-azithromycin RS (azithromycin impurity A) in the solvent mixture.

#### Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with  $\,$  end capped octadecylsilane amorphous organosilica polymer (5  $\mu m$ ) (Such as X-terra MS),
- column temperature: 60°,
- mobile phase: A. a 0.18 per cent w/v solution of anhydrous disodium hydrogen phosphate with the pH adjusted to 8.9 with dilute phosphoric acid or with dilute sodium hydroxide solution,
  - B. a mixture of 250 volumes of methanol and 750 volumes of acetonitrile,
- a gradient programme using the conditions given below,
- flow rate: 1 ml per minute,
- spectrophotometer set at 210 nm,
- injection volume: 50 μl.

Time	Mobile phase A	Mobile Phase B
(in min.)	(per cent v/v)	(per cent v/v)
0	50	50
25	45	55
30	40	60
80	25	75
81	50	50
93	50	50

Name	Relative retention time	Correction factor
Azithromycin impurity L	0.29	2.3
Azithromycin impurity M	0.37	0.6
Azithromycin impurity E	0.43	

Azithromycin impurity F	0.51	0.3
Azithromycin impurity D	0.54	
Azithromycin impurity J	0.54	
Azithromycin impurity I	0.61	
Azithromycin impurity C	0.73	
Azithromycin impurity N	0.76	0.7
Azithromycin impurity H	0.79	0.1
Azithromycin impurity A	0.83	
Azithromycin impurity P	0.92	
Azithromycin (Retention time	e:	
about 45-50 minutes)	1.0	
Azithromycin impurity O	1.23	
Azithromycin impurity G	1.26	0.2
Azithromycin impurity B	1.31	

Inject reference solution (b). The chromatogram obtained shows peaks corresponding to azithromycin and azithromycin impurity A. The test is not valid unless the resolution between these two peaks is at least 7.0.

Inject the test solution and reference solution (a). In the chromatogram obtained with the test solution, the area of any secondary peak eluting with relative retention time of about 1.3 due to 3-deoxyazithromycin (azithromycin impurity B) is not more than twice the area of principal peak in the chromatogram obtained with reference solution (a) (2.0 per cent). The sum of the areas of all the other secondary peaks is not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (3.0 per cent). Ignore any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent) ;ignore the peaks eluting before azithromycin impurity L and after azithromycin impurity B; ignore the peaks eluting before azithromycin impurity L and after azithromycin impurity B.

Other tests. Comply with the tests stated under Eye Drops

## Assay.

Solvent mixture. 20 volumes of dichloromethane and 80 volumes of methanol.

*Test solution.* Dissolve a volume of solution containing about 0.05 g of Azithromycin in 100.0 ml of the solvent mixture.

Reference solution (a). A 0.05 per cent w/v solution of azithromycin in solvent mixture.

Reference solution (b). A 0.05 per cent w/v each solution of azithromycin and azithromycin impurity A RS in solvent mixture.

### Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane vinyl plymer (5 μm) (Such as Asahipak ODP-50 is suitable),
- column temperature: 40°
- mobile phase: a mixture of 40 volumes of 0. 67 per cent w/v solution of *dipotassium hydrogen* orthophosphate adjusted to pH 11 with a 56 per cent w/v solution of potassium hydroxide and 60 volumes of acetonitrile,
- flow rate: 1 ml per minute,
- spectrophotometer set at 210 nm,
- injection volume: 10 μl.

Inject the reference solution (b). The test is not valid unless the resolution between the peaks due to impurity A and azithromycin not less than 1.5.

Inject test solutions and reference solution (a).

Calculate the content of C<sub>38</sub>H<sub>72</sub>N<sub>2</sub> O<sub>12</sub> in the eye drops.